文献速递乳腺MR

基于生理分解扩散加权MRI的影像组学机器学习预测乳腺癌新辅助化疗反应

Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.
PubMed 文献 · Radiol Imaging Cancer · 2025-01-01

本回顾性研究利用BMMR2挑战数据集(来自I-SPY 2/ACRIN 6698试验)的190例女性乳腺癌患者纵向多参数乳腺MRI数据,对DWI进行分段线性生理分解提取影像组学特征并构建提升决策树模型预测新辅助化疗后病理完全缓解。PD DWI模型AUC达0.89(95%CI: 0.81, 0.96),优于基线模型和BMMR2基准模型,决策曲线分析显示净获益更高。

要点

  • PD DWI影像组学模型预测pCR的AUC为0.89(95%CI: 0.81, 0.96),优于所有评估的基线模型(均P < .04)。
  • 决策曲线分析中PD DWI模型净获益0.17(95%CI: 0.13, 0.21),高于BMMR2基准模型的0.09(95%CI: 0.05, 0.13),P < .001。
  • 模型基于DWI生理分解获得的伪扩散、纯扩散及伪扩散分数成分提取影像组学特征。

核心结论

  • 使用PD DWI影像组学数据构建的机器学习模型在预测乳腺癌新辅助化疗后pCR方面,性能高于基线模型和基准模型。

研究设计与样本

  • 回顾性研究,纳入BMMR2挑战数据集中来自I-SPY 2/ACRIN 6698试验(NCT01042379)的190例女性参与者纵向多参数乳腺MRI(DWI和动态对比增强MRI)数据,对DWI行分段线性生理分解后提取影像组学特征并构建提升决策树模型。

诊断标准与关键数值

  • PD DWI模型预测pCR的AUC为0.89(95%CI: 0.81, 0.96),在所有评估模型中最高,较基线方法改善均P < .04;决策曲线分析净获益PD DWI模型0.17(95%CI: 0.13, 0.21)vs BMMR2基准模型0.09(95%CI: 0.05, 0.13),P < .001。

临床应用与阅片要点

  • 作者结论认为PD DWI影像组学机器学习模型在预测乳腺癌新辅助化疗后pCR方面性能高于基线及基准模型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate the performance of a machine learning model developed using radiomics data derived from physiologically decomposed diffusion-weighted MRI data for predicting pathologic complete response (pCR) following neoadjuvant chemotherapy for breast cancer compared with baseline and benchmark models. Materials and Methods This retrospective study included data from the Breast Multiparametric MRI for prediction of neoadjuvant chemotherapy Response (BMMR2) challenge dataset, comprising longitudinal multiparametric breast MRI studies (diffusion-weighted imaging [DWI] and dynamic contrast-enhanced MRI) from participants enrolled in the I-SPY 2/ACRIN 6698 trial (ClinicalTrials.gov: NCT01042379). Piecewise linear physiologic decomposition was applied to DWI data (PD DWI) to isolate pseudo-diffusion, pure-diffusion, and pseudo-diffusion fraction components for radiomics feature extraction. These features were used to develop a boosted decision tree model to predict pCR following neoadjuvant chemotherapy. Model performance was compared with performance of baseline models, including data on tumor size and mean apparent diffusion coefficient, and the BMMR2 challenge benchmark model using area under the receiver operating characteristic curve, F1 score, and positive and negative predictive values. Model calibration was assessed via the Brier score, and a decision curve analysis was performed to estimate the potential reduction in unnecessary interventions when using the proposed model. Results The study included multiparametric MRI scans from 190 female participants (mean age ± SD, 48.4 years ± 10.5). PD DWI achieved the highest area under the receiver operating characteristic curve (0.89, 95% CI: 0.81, 0.96) among all evaluated models, demonstrating statistically significant improvements over baseline approaches (all P < .04). Decision curve analysis showed that the PD DWI model provided a greater net benefit compared with the BMMR2 challenge benchmark model (0.17, 95% CI: 0.13, 0.21 vs 0.09, 95% CI: 0.05, 0.13; P < .001). Conclusion A machine learning model using radiomics data derived from PD DWI achieved higher performance than baseline and benchmark models in predicting pCR following neoadjuvant chemotherapy for breast cancer. Keywords: Image Postprocessing, MR-Diffusion Weighted Imaging, Breast, Tumor Response, Experimental Investigations ClinicalTrials.gov: NCT01042379 © RSNA, 2025.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Gilad M, Partridge SC, Iima M, et al. Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI. Radiol Imaging Cancer. 2025. PMID: 40679371. doi:10.1148/rycan.240312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。